Clinical trial
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
NCT00058799 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00058799 |
|---|---|
| Title | Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine |
| Official title | Treatment of High Risk Acute Leukemia With CD40 Ligand and IL-2 Gene Modified Autologous Skin Fibroblasts and Tumor Cells |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | Dose Level 1, Dose Level 2, Dose Level 3 |
| Enrollment | 11 |
| Start date | Jun 1, 1999 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Apr 15, 2003 |
| Last update posted | Jan 21, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: